Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests best lens combo for cataract surgery – could reduce glare and halos

NCT ID NCT07076277

Symptom relief Sponsor: Brian Shafer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two types of artificial lens implants used in cataract surgery. Some patients will get a different lens in each eye, while others will get the same lens in both eyes. The goal is to see which approach gives better vision and causes fewer problems like glare, halos, or starbursts. About 346 adults with cataracts in both eyes will take part, and their vision will be tested three months after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intraocular lens implants (PanOptix Pro and Clareon Vivity)
What this could lead to
If successful, this could help doctors choose the best lens combination for cataract patients to improve vision and reduce side effects like glare or halos.
What could go wrong
This is a relatively small, early-stage trial comparing two existing lens types, so results may not apply to all patients. Differences in vision outcomes may be small and not clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 346 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Adult patients (≥18 years old) able and willing to provide informed consent. Bilateral diagnosis of age-related cataracts. Planned bilateral cataract removal by phacoemulsification with either: Contralateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric in one eye and Clareon Vivity/Vivity Toric in the fellow eye, or Bilateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric. Expected best monocular corrected distance visual acuity (BCDVA) of 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively, as determined by the surgeon. Residual astigmatism expected to be ≤0.50 diopters in both eyes postoperatively (using toric IOLs or arcuate incisions as needed). Normal ocular findings aside from cataracts. Exclusion Criteria Corneal pathology or irregular astigmatism. Preexisting macular disease or other retinal degenerative disease expected to cause vision loss. Glaucoma. Severe dry eye disease. Nystagmus or strabismus. Zonular laxity or dehiscence, pseudoexfoliation. Any condition (in the investigator's opinion) that may affect study endpoints. Previous history of any ocular surgery, including corneal refractive surgery. Subjects desiring monovision. History of amblyopia or monofixation syndrome with poor stereoscopic vision. Total corneal higher-order aberrations (HOA) greater than 0.6 microns. Any planned simultaneous or combined procedures at the time of cataract surgery (e.g., MIGS). Participation in another clinical study that could interfere with study results. Any active ocular infection or inflammation. Pregnant, breastfeeding, or planning to become pregnant during the study (as determined by verbal inquiry).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract senile cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract Multifocal intraocular lens

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Main Line Surgery Center

    Bala-Cynwyd, Pennsylvania, 19004, United States

  • Shafer Vision Institute

    Plymouth Meeting, Pennsylvania, 19462, United States

  • VIP Eye Care

    Baltimore, Maryland, 21286, United States

  • Vance Thompson Vision

    Alexandria, Minnesota, 56308, United States

  • Vance Thompson Vision

    Bozeman, Montana, 59718, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.